One new option is dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor with solid clinical evidence in patients with type 2 diabetes mellitus (T2D) that also markedly reduces hospitalization for HF [21]. Here, SLC5A2 is linked to type 2 diabetes mellitus.